Nektar Therapeutics (NKTR): Price and Financial Metrics
Nektar Therapeutics (NKTR)
Today's Latest Price: $17.27 USD
0.80 (4.86%)
Updated Dec 2 4:00pm
Add NKTR to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
NKTR Stock Summary
- Of note is the ratio of Nektar Therapeutics's sales and general administrative expense to its total operating expenses; merely 9.22% of US stocks have a lower such ratio.
- NKTR's price/sales ratio is 18.09; that's higher than the P/S ratio of 90.81% of US stocks.
- With a year-over-year growth in debt of -61.66%, Nektar Therapeutics's debt growth rate surpasses only 4.65% of about US stocks.
- If you're looking for stocks that are quantitatively similar to Nektar Therapeutics, a group of peers worth examining would be NERV, AGIO, ASMB, PRQR, and CLLS.
- Visit NKTR's SEC page to see the company's official filings. To visit the company's web site, go to www.nektar.com.
NKTR Stock Price Chart Interactive Chart >
NKTR Price/Volume Stats
| Current price | $17.27 | 52-week high | $28.60 |
| Prev. close | $16.47 | 52-week low | $13.63 |
| Day low | $16.50 | Volume | 938,986 |
| Day high | $17.55 | Avg. volume | 1,363,094 |
| 50-day MA | $17.01 | Dividend yield | N/A |
| 200-day MA | $19.69 | Market Cap | 3.10B |
Nektar Therapeutics (NKTR) Company Bio
Nektar Therapeutics is a biopharmaceutical company, developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.
Loading social stream, please wait...